Drugs / ELUBRIXIN
ELUBRIXIN
also known as
SB-656933 · SB-656933-AAA · Elubrixin tosilate · ELUBRIXIN TOSYLATE · Elubrixina · Elubrixine · SB-656933-AAF
Small molecule targets CXCR2
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00615576 | Mar → Jul 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00605761 | Feb → Dec 2008 | cystic fibrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00551811 | Oct 2007 → Jul 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00504439 | Jun → Sep 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00903201 | Sep 2009 → Dec 2010 | cystic fibrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00748410 | Jan → Dec 2009 | ulcerative colitis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELUBRIXIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Known as | Elubrixin tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Known as | ELUBRIXIN TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Known as | Elubrixina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Known as | Elubrixine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Known as | SB-656933 | “The objective of this study was to evaluate the safety, tolerability and pharmacodynamics of SB-656933, an oral CXCR2 antagonist.” PMID 22995323 ↗ Sep 2012 |
| Known as | SB-656933-AAA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00504439 ↗ |
| Known as | SB-656933-AAF | ChEMBL registry synonym — accepted as the source's own label CHEMBL2178579 ↗ |
| Modality | Small molecule | — CHEMBL2178579 ↗ |
| Route | Oral | “The tablets will be administered orally.” NCT00504439 ↗ |
| Target | CXCR2 | “SB-656933, an oral CXCR2 antagonist” PMID 22995323 ↗ Sep 2012 |